NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Nov 16, 2029 (in 1102 days)
Similar opportunities open now
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026Up to $150K
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026Up to $300K
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Apr 2027
- NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Dec 2030
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 2028
Classification and identifiers
- Solicitation number
- PAR-28-072
- Assistance listing (CFDA)
- 93.867
Amount
Amount not listed here. Check the official program.
Who can apply
Public colleges and universities and Private colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesFaith-based or Community-based OrganizationsRegional Organizations…
About this opportunity
The purpose of NEI’s Translational Research program is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to three years and will support research that is in the final states of preclinical development with potential for near-term clinical develop...